Published in Hepatitis Weekly, September 16th, 1996
Virus titer determinations showed at least seven log reduction was achieved by heat treatment for each of five different viruses tested, reported M. Azari and colleagues, Blood Substitutes Program, Baxter Healthcare Corporation, Round Lake, Illinois.
Azari et al. described their experiments to assess the ability of the heat treatment step used in the manufacture of Baxter's product, diaspirin crosslinked hemoglobin (DCLHb), to inactivate viruses at the VI International Symposium on Blood Substitutes, held August 5-7, 1996, at McGill University, in Montreal, Quebec,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.